LUNG CANCER

Latest News

July 27th 2018

Shepherd Says Translational Research in EGFR+ Lung Cancer Thanks to Molecular Pathology

In a keynote address by Frances A. Shepherd, MD, FRCPC, OOnt, OC, during the <em>19th Annual </em>International Lung Cancer Congress, Shepherd expressed that <em>EGFR-</em>mutant non–small cell lung cancer (NSCLC) is a model for how far the field of lung cancer has progressed in the past decade, thanks in large part to molecular pathologists. 

July 27th 2018

Immunotherapy Requires Precision Approach for NSCLC

By Gina Columbus

July 26th 2018

Novel Targeted Therapies Emerging for NSCLC

By Silas Inman

July 26th 2018

Brigatinib Superior to Crizotinib in ALK+ NSCLC

By Jason M. Broderick

July 20th 2018

Frontline Atezolizumab Regimen Prolongs PFS in Nonsquamous NSCLC

By Jason M. Broderick

Latest Videos

Driver Mutation NSCLC: Combining Targeted and I-O Therapy

Trials of I-O Therapy in Driver Mutation NSCLC

Considering Use of I-O Therapy in Driver Mutation NSCLC

Dual Checkpoint Inhibition in NSCLC: CheckMate-227

IMpower150: Combining VEGF and I-O Therapy in NSCLC

Chemo-Immunotherapy in NSCLC: The KEYNOTE-189 Trial

Benefit of Pembrolizumab in NSCLC: The KEYNOTE Trials

Treatment of BRAF-Mutant NSCLC

Sequencing Therapy in ALK/ROS1-Rearranged NSCLC

ALK/ROS1-Rearranged NSCLC: Approaching Therapy

CME Content

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Seth A. Wander, MD, PhD; Girish Kunapareddy, MD

Video

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Iowa

Virginia Kaklamani, MD, DSc; Jack W. Erter III, MD, MMHC

Virtual Event

Arkansas Association of Cancer Professionals

2 Sessions are Available!

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | South Carolina Oncology Society

Seth A. Wander, MD, PhD; Kit Lu, MD

In-Person Event

Immune Therapies in Practice in 2026: Cellular Therapies, ADCs, Bispecifics, and Beyond

May 22, 2026

Video

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Minnesota

Neil M. Iyengar, MD; Kimberly Ku, MD

Video

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Texas

Sheila Donnelly, MD; Virginia Kaklamani, MD, DSc

Virtual Event

Updates from Berlin: Oral SERDs in HR+/HER2- Metastatic Breast Cancer – What the Latest Data Really Tell Us

May 27, 2026

Multimedia

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Reshma Jagsi, MD, DPhil; Kevin Kalinsky, MD, MS; Hope S. Rugo, MD, FASCO; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

In-Person + Virtual Event

Go to PER in Chicago

May 29-31, 2026

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice Society

Seth A. Wander, MD, PhD; Kamel Abou Hussein, MD

Video

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Washington

Alison K. Conlin, MD; Neil M. Iyengar, MD

Virtual Event

Updates from Chicago: Oral SERDs in HR+/HER2- Metastatic Breast Cancer – What the Latest Data Really Tell Us

June 8, 2026

Video

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Wyoming & Montana

Yan Ji, MD; Neil M. Iyengar, MD

Video

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – North Carolina

Girish Kunapareddy, MD; Sara M. Tolaney, MD, MPH

Virtual Event

Iowa Oncology Society

1 Session is Available!

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Nevada Oncology Society

Seth A. Wander, MD, PhD; Ruta D. Rao, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Marla D. Lipsyc-Sharf, MD; Richard Zelkowitz, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society

Seth A. Wander, MD, PhD; Kate Baxstrom, MD

Virtual Event

Kansas Society of Clinical Oncology

1 Session is Available!

Virtual Event

Louisiana Oncology Society

1 Session is Available!

Virtual Event

Missouri Oncology Society

1 Session is Available!

Virtual Event

New Mexico Society of Clinical Oncology

1 Session is Available!

Video

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Video

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO; Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; Paolo Tarantino, MD

In-Person + Virtual Event

25th Annual International Congress on the Future of Breast Cancer® East

July 10-11, 2026

Video

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Multimedia

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Multimedia

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Multimedia

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Multimedia

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Multimedia

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Video

24th Annual International Congress on the Future of Breast Cancer® East

Joyce O’Shaughnessy, MD

Multimedia

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Multimedia

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Video

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

Video

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

More News

Looking Toward the Future of Targeting Gene Fusions

ByDanielle Ternyila

July 19th 2018

Alexander Drilon, MD, discusses the data currently available with targeting gene fusions, and shares insight into what is on the horizon in this area.

Supportive Care in Metastatic NSCLC

July 19th 2018

Using Antiangiogenic Therapy in Stage 4 NSCLC

July 19th 2018

Second-Line Therapy in Stage 4 NSCLC

July 19th 2018

Using First-Line Immunotherapy in Stage 4 NSCLC

July 19th 2018

Diagnosing A Patient With Stage 4 NSCLC

July 19th 2018

Clinical Management of NSCLC With Bone Metastases

July 19th 2018

Clinical Management of NSCLC With Bone Metastases

Treatment After Progression on Anti-VEGF Therapy

July 19th 2018

Anti-VEGF Therapy in Advanced Squamous NSCLC

July 19th 2018

Progression After Chemotherapy in Advanced Squamous NSCLC

July 19th 2018

Frontline Treatment Options in Advanced Squamous NSCLC

July 19th 2018

Role of Molecular Profiling in Squamous NSCLC

July 19th 2018

Case: Advanced Squamous NSCLC With Rapid Progression

July 19th 2018

Managing Metastatic NSCLC With Rapid Progression

July 19th 2018

Managing Metastatic NSCLC With Rapid Progression

Updates in the Use of Liquid Biopsies for Multiple Tumor Types

ByWafik El-Deiry, MD, PhD, FACP

July 12th 2018

Wafik El-Deiry, MD, PhD, FACP, deputy cancer center director, Translational Research Program, co-leader, Molecular Therapeutics Program, professor, Department Hematology/Oncology, Fox Chase Cancer Center, discusses updates in the use of liquid biopsies for multiple tumor types during the 2018 ASCO Annual Meeting.

LUNG CANCER

Latest News

Latest Videos

Driver Mutation NSCLC: Combining Targeted and I-O Therapy

Trials of I-O Therapy in Driver Mutation NSCLC

Considering Use of I-O Therapy in Driver Mutation NSCLC

Dual Checkpoint Inhibition in NSCLC: CheckMate-227

IMpower150: Combining VEGF and I-O Therapy in NSCLC

Chemo-Immunotherapy in NSCLC: The KEYNOTE-189 Trial

Benefit of Pembrolizumab in NSCLC: The KEYNOTE Trials

Treatment of BRAF-Mutant NSCLC

Sequencing Therapy in ALK/ROS1-Rearranged NSCLC

ALK/ROS1-Rearranged NSCLC: Approaching Therapy

CME Content

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Iowa

Arkansas Association of Cancer Professionals

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | South Carolina Oncology Society

Immune Therapies in Practice in 2026: Cellular Therapies, ADCs, Bispecifics, and Beyond

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Minnesota

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Texas

Updates from Berlin: Oral SERDs in HR+/HER2- Metastatic Breast Cancer – What the Latest Data Really Tell Us

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Go to PER in Chicago

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice Society

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Washington

Updates from Chicago: Oral SERDs in HR+/HER2- Metastatic Breast Cancer – What the Latest Data Really Tell Us

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Wyoming & Montana

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – North Carolina

Iowa Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Nevada Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society

Kansas Society of Clinical Oncology

Louisiana Oncology Society

Missouri Oncology Society

New Mexico Society of Clinical Oncology

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

25th Annual International Congress on the Future of Breast Cancer® East

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

24th Annual International Congress on the Future of Breast Cancer® East

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

More News

Looking Toward the Future of Targeting Gene Fusions

Supportive Care in Metastatic NSCLC

Using Antiangiogenic Therapy in Stage 4 NSCLC

Second-Line Therapy in Stage 4 NSCLC

Using First-Line Immunotherapy in Stage 4 NSCLC

Diagnosing A Patient With Stage 4 NSCLC

Clinical Management of NSCLC With Bone Metastases

Treatment After Progression on Anti-VEGF Therapy

Anti-VEGF Therapy in Advanced Squamous NSCLC

Progression After Chemotherapy in Advanced Squamous NSCLC

Frontline Treatment Options in Advanced Squamous NSCLC

Role of Molecular Profiling in Squamous NSCLC

Case: Advanced Squamous NSCLC With Rapid Progression

Managing Metastatic NSCLC With Rapid Progression

Updates in the Use of Liquid Biopsies for Multiple Tumor Types

PIVOT-02: Implications and Next Steps in Research

Efficacy of NKTR-214 in the Tumor Microenvironment

Biomarker Sampling in Metastatic Melanoma

PIVOT-02 for First-Line Stage IV Melanoma

Pegylation Chemistry of NKTR-214 in Melanoma

Pathophysiology of the Tumor Microenvironment in Melanoma

The PIVOT-02 Trial: NKTR-214 With Nivolumab

Synergistic Activity of NKTR-214 With Nivolumab

The Hype and the Hope of Immuno-Oncology Agents

Who Is Winning the War on Cancer?